These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Is there a treatment for Alzheimer's disease?]. Joray S; Ghika J; von Gunten A; Büla C; Gold G; Assal F Rev Med Suisse; 2005 May; 1(18):1201-2, 1205-6, 1208. PubMed ID: 15977708 [TBL] [Abstract][Full Text] [Related]
7. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease. Relkin NR Expert Rev Neurother; 2007 Jun; 7(6):735-48. PubMed ID: 17561789 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of Alzheimer's disease with acetylcholinesterase inhibitors]. Dartigues JF; Poncet M Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F107. PubMed ID: 18680827 [No Abstract] [Full Text] [Related]
9. [Treatment of Alzheimer's disease utilising the best available evidence-based medicine -- utopia?]. Stoppe G; Pirk O; Haupt M Gesundheitswesen; 2005 Jan; 67(1):20-6. PubMed ID: 15672302 [TBL] [Abstract][Full Text] [Related]
10. [Influence of treatment with acetyl-cholinesterase inhibitors on psychopathological symptoms in Alzheimer's disease]. Rösler M; Frey U Fortschr Neurol Psychiatr; 2002 Feb; 70(2):78-83. PubMed ID: 11823923 [TBL] [Abstract][Full Text] [Related]
11. [Acetylcholinesterase inhibitors]. Rioux S Rev Med Suisse Romande; 2003 Jul; 123(7):471-4. PubMed ID: 15088511 [TBL] [Abstract][Full Text] [Related]
12. Alzheimer's drugs deliver fringe benefits. Cholinesterase inhibitors improve more than just memory. Auerbach SH Health News; 2003 Mar; 9(3):1-2. PubMed ID: 12703432 [No Abstract] [Full Text] [Related]
13. Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease. Prescrire Int; 2001 Dec; 10(56):180-1. PubMed ID: 11824442 [TBL] [Abstract][Full Text] [Related]
15. Update on Alzheimer drugs (galantamine). Raskind MA Neurologist; 2003 Sep; 9(5):235-40. PubMed ID: 12971834 [TBL] [Abstract][Full Text] [Related]
16. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine]. Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553 [TBL] [Abstract][Full Text] [Related]
18. Impact of nutritional status on the evolution of Alzheimer's disease and on response to acetylcholinesterase inhibitor treatment. Vellas B; Lauque S; Gillette-Guyonnet S; Andrieu S; Cortes F; Nourhashémi F; Cantet C; Ousset PJ; Grandjean H; J Nutr Health Aging; 2005; 9(2):75-80. PubMed ID: 15791349 [TBL] [Abstract][Full Text] [Related]
19. Should cholinesterase inhibitors be used to treat Alzheimer's disease? Finucane TE; Gilstad JR Nat Clin Pract Neurol; 2006 Mar; 2(3):118-9. PubMed ID: 16932534 [No Abstract] [Full Text] [Related]
20. [Cholinergic deficiency syndrome as an indicator for the cholinesterase inhibitors]. Lemstra AW; Eikelenboom P; van Gool WA Ned Tijdschr Geneeskd; 2003 Nov; 147(45):2201-3. PubMed ID: 14640055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]